| abstract |
PIGR-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PIGR-2 polypeptides and polynucleotides in the design of protocols for the treatment of rheumatoid arthritis (RA), Multiple Sclerosis (MS), psoriasis, Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD), among others and diagnostic assays for such conditions. |